adaptnow
$AEON As of November 16, 2026, the Company had received approximately $6.2 million in gross proceeds from exercises of these warrants, providing additional capital to support the continued advancement of the ABP-450 development program. Any warrants remaining unexercised will expire on November 16, 2026.
1

:format(webp)/https%3A%2F%2Fst-everywhere-cms-prod.s3.us-east-1.amazonaws.com%2Flarge_biotech_stocks_chart_resized_a25a478437.jpg)
:format(webp)/https%3A%2F%2Fst-everywhere-cms-prod.s3.us-east-1.amazonaws.com%2Fbiotech_stocks_chart_resized_a25a478437.jpg)